Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Schwid

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Neurology|August 17, 1999
Targeting immunotherapy in multiple sclerosis: a near hit and a clear missS R Schwid, J H Noseworthy
Neurology|May 10, 2000
Lessons from linomide: a failed trial, but not a failureS R Schwid, J L Trotter
Neurology|June 27, 2001
The cost of delaying treatment in multiple sclerosis: what is lost is not regainedS R Schwid, C T Bever
Archives of Neurology|October 6, 1997
Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1bS R Schwid, A D Goodman, D H Mattson
The American Journal of Clinical Nutrition|April 1, 1992
Nicotine effects on body weight: a regulatory perspectiveS R Schwid, M D Hirvonen, R E Keesey
Journal of Neuroimmunology|July 30, 1999
Therapy of relapsing multiple sclerosis. Treatment approaches for nonrespondersJ A Cohen, J L Carter, R P Kinkel, et al.
Neurology|May 10, 2006
Safety of rasagiline in elderly patients with Parkinson diseaseC G Goetz, S R Schwid, S W Eberly, et al.
Neurology|July 30, 2008
Quantitative risk-benefit analysis of natalizumabJ P Thompson, K Noyes, E R Dorsey, et al.
Archives of Neurology|August 1, 1996
Sporadic corticosteroid pulses and osteoporosis in multiple sclerosisS R Schwid, A D Goodman, J E Puzas, et al.
Neurology|April 24, 2002
Quantitative functional measures in MS: what is a reliable change?S R Schwid, A D Goodman, M P McDermott, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Neurology|August 17, 1999
Targeting immunotherapy in multiple sclerosis: a near hit and a clear missS R Schwid, J H Noseworthy
Neurology|May 10, 2000
Lessons from linomide: a failed trial, but not a failureS R Schwid, J L Trotter
Neurology|June 27, 2001
The cost of delaying treatment in multiple sclerosis: what is lost is not regainedS R Schwid, C T Bever
Archives of Neurology|October 6, 1997
Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1bS R Schwid, A D Goodman, D H Mattson
The American Journal of Clinical Nutrition|April 1, 1992
Nicotine effects on body weight: a regulatory perspectiveS R Schwid, M D Hirvonen, R E Keesey
Journal of Neuroimmunology|July 30, 1999
Therapy of relapsing multiple sclerosis. Treatment approaches for nonrespondersJ A Cohen, J L Carter, R P Kinkel, et al.
Neurology|May 10, 2006
Safety of rasagiline in elderly patients with Parkinson diseaseC G Goetz, S R Schwid, S W Eberly, et al.
Neurology|July 30, 2008
Quantitative risk-benefit analysis of natalizumabJ P Thompson, K Noyes, E R Dorsey, et al.
Archives of Neurology|August 1, 1996
Sporadic corticosteroid pulses and osteoporosis in multiple sclerosisS R Schwid, A D Goodman, J E Puzas, et al.
Neurology|April 24, 2002
Quantitative functional measures in MS: what is a reliable change?S R Schwid, A D Goodman, M P McDermott, et al.
Pageof 3